Skip Navigation



JAC Advance Access published online on June 10, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki197
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/2/349    most recent
dki197v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betriu, C.
Right arrow Articles by Picazo, J. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org
Received March 3, 2005
Revised May 19, 2005
Accepted May 20, 2005

Original article

In vitro activity of tigecycline against Bacteroides species

C. Betriu 1*, E. Culebras 1, M. Gómez 1, I. Rodríguez-Avial 1, and J. J. Picazo 1

1 Department of Clinical Microbiology, Hospital Clínico San Carlos, 28040 Madrid, Spain

* To whom correspondence should be addressed.
C. Betriu, E-mail: cbetriu{at}efd.net


  Abstract

Objectives: To ascertain the current susceptibility patterns of members of the Bacteroides fragilis group in our hospital and to assess the in vitro activity of tigecycline against these organisms.

Methods: A total of 400 non-duplicate clinical isolates of the B. fragilis group collected from 2000 to 2002 were studied. Susceptibility testing was performed according to the reference agar dilution method described by the NCCLS. The following antimicrobials were tested: tigecycline, clindamycin, metronidazole, chloramphenicol, cefoxitin, imipenem, amoxicillin-clavulanate and piperacillin-tazobactam.

Results: All strains were susceptible to metronidazole and chloramphenicol. For clindamycin and cefoxitin, the overall susceptibility rates were 59.5% and 83%, respectively. Imipenem and piperacillin-tazobactam were the most active {beta}-lactam agents tested. Tigecycline inhibited 89.8% of the strains at a concentration of 8 mg/L with an MIC range of ≤0.01 to >16 mg/L. By comparing the MIC50 and MIC90 values of tigecycline among the various species of the group, B. fragilis, Bacteroides thetaiotaomicron and Bacteroides vulgatus were the most susceptible (MIC50/MIC90s of 0.5-1/8 mg/L).

Conclusions: Tigecycline exhibited activity against most isolates of the B. fragilis group tested. These results indicate that tigecycline may be useful in the treatment and prophylaxis of infections involving these organisms.

Keywords: susceptibility; glycylcyclines; Bacteroides fragilis group.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Microbiol. Rev.Home page
H. M. Wexler
Bacteroides: the Good, the Bad, and the Nitty-Gritty
Clin. Microbiol. Rev., October 1, 2007; 20(4): 593 - 621.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. R. Snydman, N. V. Jacobus, L. A. McDermott, R. Ruthazer, Y. Golan, E. J. C. Goldstein, S. M. Finegold, L. J. Harrell, D. W. Hecht, S. G. Jenkins, et al.
National Survey on the Susceptibility of Bacteroides fragilis Group: Report and Analysis of Trends in the United States from 1997 to 2004
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1649 - 1655.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
E. J. C. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez
Comparative In Vitro Susceptibilities of 396 Unusual Anaerobic Strains to Tigecycline and Eight Other Antimicrobial Agents
Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3507 - 3513.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. Kasbekar
Tigecycline: A new glycylcycline antimicrobial agent.
Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1235 - 1243.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.